Maviret and Vosevi, two new drugs for the treatment of chronic hepatitis C virus (HCV) infection in adults, have been approved by the European Medicines Agency.

HCV infection represents the most common single cause of liver transplantation in the EU and it affects between 0.4% and 3.5% of the population. In Europe, approximately 15 million people are chronically infected with HCV.

Maviret and Vosevi are effective against all genotypes of the virus. They have the role to block the action of proteins essential for HCV replication reaching a high degree of recovery without the need for interferon administration which are known for their serious side effects and poor tolerability.

Maviret is composed of two antiviral agents: glecaprevir (inhibitor of HCV NS3/4A protease) and pibrentasvir (inhibitor of HCV NS5A) and its effect were studied on 2,376 patients. Twelve weeks after the end of treatment, the HCV could not be detected in over 90% of patients.

The second drug, Vosevi, contains three active ingredients: sofosbuvir (nucleotide analogue non-structural protein NS5B polymerase inhibitor), velpatasvir (inhibitor of HCV NS5A) and voxilaprevir (HCV NS3/4A protease inhibitor). Its effects were studied on over 1,700 patients and twelve weeks after the treatment, over 90% of patients have no HCV.

For more information please access the European Medicine Agency .